Valcyte is currently approved as treatment of AIDS-related cytomegalovirus (CMV) retinitis, prevention of CMV disease in kidney, heart, or kidney-pancreas transplant adult patients at high risk, and prevention of CMV disease in kidney and heart transplant pediatric patients (4 months to 16 years old) at high risk.
Valganciclovir is an L-valyl ester (prodrug) of ganciclovir that exists as a mixture of two diastereomers. Both diastereomers are rapidly converted to ganciclovir by intestinal and hepatic esterases. Ganciclovir is a synthetic analogue of 2′-deoxyguanosine, which inhibits replication of human CMV in cell culture and in vivo.
Valganciclovir Tablets are available in a 450mg strength.
For more information call (866) 733-3952 or visit DrReddys.com.